Multiple Myeloma | Clinical

Motixafortide Plus G-SCF Prepares 88.3% of Patients With Multiple Myeloma for Transplant

May 06, 2021

In patients with multiple myeloma, the combination of motixafortide and granulocyte colony-stimulating factor achieved a 4.9-fold increase in hematopoietic stem-cell mobilization, and prepared most patients for autologous stem cell transplant, meeting both the primary and main secondary endpoints of the GENESIS Study.